At ASH in San Diego, the CML education session was entitled 'With Great Success Comes Great Responsibility'. Professors Jane Apperley, Timothy Hughes and Charles Craddock gave respective presentations on the treatment of CML with TKIs, molecular monitoring to aid clinical decision making and the role of transplantation in managing CML. Below are interviews from the presenters on their perspectives on the session.
These summaries are brought to you with support from Bristol Myers Squibb.
In addition, we are pleased to be able to offer you a complete scientific summary of the education session on CML. This also contains a summary of relevant abstracts on; TFR failure, resistance and new drug development.
Download the scientific summary report here
Professor Jane Apperley
Imperial College London, London, UK
Jane Apperley described the outcome of newly diagnosed patients newly treated with first or second generation TKIs. She discussed balancing the desire to achieve the deep molecular responses that permit trials of TKI discontinuation with the potential adverse effects of earlier use of the more potent TKI's, and provided pragmatic advice regarding treatment decisions.
Professor Timothy Hughes
Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, Australia
Tim Hughes explored the appropriate time-dependent molecular targets for CML patients on TKI and the reasons why those targets differ, especially when considering treatment discontination. He also discussed the facts that influence the choice of TKI when molecular responses are not optimal and highlighted the critical role of molecular monitoring in managaging treatment-free remission.
Professor Charles Craddock
Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK
Charles Craddock summarised the results of alloSCT in all phases of CML and discussed factors affecting decision-making now that increased donor availability and reduced intensity conditioning regimes have increased the number of transplant eligible patients. As disease relapse remains a major cause of treatment failure he focused on emerging peri- and post-transplant strategies to improve the outcome.
Perspectives on the scientific aspects of the meeting from Professor Daniela Krause
Georg-Speyer Haus
University of Frankfurt (Germany)
{rscomments off}
Perspectives on the clinical aspects of the meeting from Professor Jorge Cortes
MD Anderson Cancer Center
University of Texas, Houston (USA)
{rscomments off}
In Spanish:
Perspectivas sobre nuevas estudios clínicos y cómo se transfieren al mundo real - especialmente en países en vía de desarollo
Dr Carolina Pavlovsky
FUNDALEU - Fundación para combatir la leucemia
Buenos Aires - Argentina